Research Article
Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis
Published Online:17 Feb 2014https://doi.org/10.2217/pgs.13.230
Abstract
Background: Genetic variants in NAT2 are associated with pharmacokinetic variation of isoniazid, the cornerstone of antituberculosis treatment. We investigated the acetylator genotype and phenotype in children on antituberculosis treatment that were previously shown to have low plasma isoniazid levels. Materials & methods:NAT2 genotyping and phenotyping, represented as metabolic ratio of acetylisoniazid over isoniazid and as isoniazid half-life, were performed in 30 Venezuelan children. Results: Most children carried genotypes resulting in an intermediate or low enzyme activity (43 and 40%, respectively). Isoniazid exposure differed between genotypically slow and rapid acetylators (13.3 vs 4.5 h×mg/l, p < 0.01). Both the metabolic ratio as well as the half-life of isoniazid distinguished genotypically slow from genotypically rapid or intermediate acetylators (all p ≤ 0.01). Conclusion: In Venezuelan children a clear difference in isoniazid pharmacokinetics and acetylator phenotype between genotypically slow and genotypically intermediate or rapid acetylating children was observed.
Original submitted 31 July 2013; Revision submitted 11 November 2013
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Parkin DP, Vandenplas S, Botha FJ et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med.155,1717–1722 (1997).
- 2 Aarnoutse R. Pharmacogenetics of Antituberculosis drugs. In: Antituberculosis Chemotherapy (Progress in Respiratory Research) (1st Edition). Donald PR, van Helden PD (Eds). Karger, Basel, 176–190 (2011).
- 3 Donald PR, Parkin DP, Seifart HI et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur. J. Clin. Pharmacol.63,633–639 (2007).
- 4 Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J. Gastroenterol. Hepatol.26,312–318 (2011).
- 5 Teixeira RL, Morato RG, Cabello PH et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem. Inst. Oswaldo Cruz106,716–724 (2011).
- 6 Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics9,311–321 (2008).
- 7 Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr. Rep.3,e16 (2011).
- 8 Wu SS, Chao CS, Vargas JH et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation84,173–179 (2007).
- 9 Ellard GA. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle65,211–227 (1984).
- 10 Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British medical research council tuberculosis units, 1946–1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis.3,S231–S279 (1999).
- 11 Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis.55,169–177 (2012).▪▪ Pharmacokinetic variability of isoniazid is associated with microbiological failure and acquired drug resistance.
- 12 Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother.49,1733–1738 (2005).
- 13 Azuma J, Ohno M, Kubota R et al.NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur. J. Clin. Pharmacol.69,1091–1101 (2013).▪▪ The first randomized controlled trial for pharmacogenetics-based isoniazid therapy demonstrates that a NAT2 genotype-guided regimen results in a much lower incidence of isoniazid-related liver injury or early treatment failure than the conventional standard regimen in adults.
- 14 Gervasini G, Benitez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur. J. Clin. Pharmacol.66,755–774 (2010).
- 15 Miscoria G, Leneveu A, Walle C, Roux A. Application of a method of analysis using high performance liquid chromatography of isoniazid and acetylisoniazid to determine the phenotype of acetylation. Ann. Biol. Clin. (Paris)46,734–740 (1988).
- 16 Hutchings A, Routledge PA. A simple method for determining acetylator phenotype using isoniazid. Br. J. Clin. Pharmacol.22,343–345 (1986).
- 17 Seifart HI, Parkin DP, Botha FJ, Donald PR, van der Walt BJ. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol. Drug Saf.10,127–134 (2001).▪ Metabolic ratio as a method for acetylator phenotyping is a reliable parameter to discriminate between genotypically slow, intermediate and fast acetylors in adults.
- 18 Schaaf HS, Parkin DP, Seifart HI et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child.90,614–618 (2005).
- 19 Verhagen LM, Lopez D, Hermans PW et al. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. Trop. Med. Int. Health12,1449–1456 (2012).
- 20 Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet.73,1162–1169 (2003).
- 21 Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics11,207–215 (2001).
- 22 Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis28,1665–1671 (2007).
- 23 Pariente-Khayat A, Rey E, Gendrel D et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin. Pharmacol. Ther.62,377–383 (1997).▪ The first study that shows that the cumulative frequency of fast acetylators according to metabolic ratio increases with age, indicating the maturation of isoniazid acetylation during the first 4 years of life.
- 24 Zhu R, Kiser JJ, Seifart HI et al. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J. Clin. Pharmacol.52,511–519 (2012).▪ Different NAT2 enzyme maturation profiles are demonstrated for genotypically fast, intermediate and slow acetylators in perinatally HIV-exposed infants in South Africa.
- 25 Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc.4,1073–1081 (2009).
- 26 Patin E, Barreiro LB, Sabeti PC et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am. J. Hum. Genet.78,423–436 (2006).
- 27 Fuselli S, Gilman RH, Chanock SJ et al. Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across native American populations and high intra-population diversity. Pharmacogenomics J.7,144–152 (2007).
- 28 Kang TS, Jin SK, Lee JE, Woo SW, Roh J. Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups. J. Clin. Pharm. Ther.34,709–718 (2009).
- 29 Sekine A, Saito S, Iida A et al. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population. J. Hum. Genet.46,314–319 (2001).
- 30 Teixeira RL, Miranda AB, Pacheco AG et al. Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat. Res.624,31–40 (2007).
- 31 Martínez H, Rodríguez-Larralde A, Izaguirre MH, de Guerra DC. Admixture estimates for Caracas, Venezuela, based on autosomal, Y-chromosome, and mtDNA markers. Hum. Biol.79,201–213 (2007).
- 32 Patin E, Harmant C, Kidd KK et al. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum. Mutat.27(7),720 (2006).
- 33 Garte S, Gaspari L, Alexandrie AK et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev.10,1239–1248 (2001).
- 34 Chamorro JG, Castagnino JP, Musella RM et al. The distribution of allelic and genotypic frequencies of N-acetyltransferase-2 variants in an Argentine population. J. Infect. Dev. Ctries.6,671–674 (2012).
- 35 Makhatadze NJ, Franco MT, Layrisse Z. HLA class I and class II allele and haplotype distribution in the Venezuelan population. Hum. Immunol.55,53–58 (1997).
- 36 McKeown A. Global migration 1846–1940. J. World Hist.15,155–189 (2004).
- 37 Schaaf HS, Willemse M, Cilliers K et al. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med.7,19 (2009).
- 38 Rey E, Gendrel D, Treluyer JM et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam. Clin. Pharmacol.15,355–359 (2001).▪ Two acetylator groups, that is, fast and slow acetylators, that are related to significant differences in the pharmacokinetics of isoniazid can be distinguished based on phenotyping according to the metabolic ratio in children.
- 39 Kiser JJ, Zhu R, D’Argenio DZ et al. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Ther. Drug Monit.34(4),446–451 (2012).
- 101 WHO. Factsheet on childhood TB. No more crying, no more dying. Towards zero TB deaths in children. WHO, Geneva, Switzerland (2012). www.stoptb.org/assets/documents/news/ChildhoodTB_report_singles.pdf
- 102 Arylamine N-acetyltransferase Gene Nomenclature Committee. Consensus Human Arylamine N-acetyltransferase Gene Nomenclature. http://nat.mbg.duth.gr
- 103 WHO. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. WHO, Geneva, Switzerland (2009).www.who.int/tb/challenges/interim_paediatric_fdc_dosing_instructions_sept09.pdf
